Status:
RECRUITING
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
20-70 years
Brief Summary
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied
Detailed Description
100 cases in normal ovarian control group, 100 cases in benign ovarian disease group and 100 cases in malignant ovarian epithelial carcinoma group will be studied. Change regularity of ovarian cancer ...
Eligibility Criteria
Inclusion
- Female
- Normal ovary control
- Ovarian benign disease
- Ovarian malignant epithelial carcinoma
Exclusion
- Male
- Age above 70
- Suffering from other malignant tumors
- Non-compliant patient
Key Trial Info
Start Date :
February 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 3 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05410015
Start Date
February 3 2022
End Date
February 3 2026
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China